These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39326009)

  • 1. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
    Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG
    J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38877972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
    J Crohns Colitis; 2024 Aug; 18(8):1270-1282. PubMed ID: 38613425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.
    Takeuchi K; Hisamatsu T; Nakase H; Matsuoka K; Keating M; Yuasa H; Oe M; Arai S; Mazur R; Hibi T
    Digestion; 2024 Sep; ():1-9. PubMed ID: 39317165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
    Magro F; Peyrin-Biroulet L; Sands BE; Danese S; Jairath V; Goetsch M; Bhattacharjee A; Wu J; Branquinho D; Modesto I; Feagan BG
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39089519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in UC: Analyses of the ELEVATE UC Clinical Programme.
    Sands BE; Leung Y; Rubin DT; Gecse KB; Panés J; Goetsch M; Wang W; Woolcott JC; Smith CC; Wosik K; Schreiber S
    J Crohns Colitis; 2024 Sep; ():. PubMed ID: 39306680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
    Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
    J Crohns Colitis; 2024 Oct; 18(10):1596-1605. PubMed ID: 38700040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
    Jairath V; Rubin DT; Verstockt B; Çekin AH; Abreu MT; Lees CW; Fellmann M; Woolcott JC; Crosby C; Wu J; Bhattacharjee A; Herman D; Gu G; Siegmund B
    Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38899786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
    Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
    J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
    Schreiber S; Feagan BG; Peyrin-Biroulet L; Vermeire S; Faes M; Harris K; Oortwijn A; Daniele P; Patel H; Danese S
    J Crohns Colitis; 2023 Jun; 17(6):863-875. PubMed ID: 36756874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
    Peyrin-Biroulet L; Louis E; Loftus EV; Lacerda A; Zhou Q; Sanchez Gonzalez Y; Ghosh S
    Adv Ther; 2021 May; 38(5):2339-2352. PubMed ID: 33755884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
    Dubinsky MC; Armuzzi A; Gecse KB; Ullman T; Bushmakin AG; DiBonaventura M; Cappelleri JC; Connelly SB; Woolcott JC; Salese L
    Dig Dis; 2023; 41(4):604-614. PubMed ID: 36603566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.
    Willian MK; D'Haens G; Yarlas A; Joshi AV
    J Patient Rep Outcomes; 2018 Dec; 2():22. PubMed ID: 30294708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.